Medical Devices

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

Amid financial headwinds, radiation therapy firm Accuray appoints a proven sales leader to spearhead a critical commercial transformation.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

With record revenue and A-list fans, British MedTech firm LYMA is doubling down on the US market, blending clinical data with celebrity appeal.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

A new partnership offers a turnkey imaging system for medical device makers, aiming to slash development time and enhance surgical precision in arthroscopy.

FDA clears Allevion's Vantage™, a disposable kit with integrated visualization that targets bone growth, aiming to transform spinal decompression.

A major lab expansion in Massachusetts aims to slash preclinical timelines for the most promising new cancer treatments, including advanced radiotherapies.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

A pivotal clinical trial for PMM2-CDG, a devastating genetic disorder with no approved treatments, has completed enrollment, offering hope to thousands.

Dr. Amit Singal, a leading hepatologist, joins Curve Biosciences as CMO, aiming to leverage AI to find chronic liver disease before it becomes incurable.

After 40 years as a silent partner to global brands, Intercon Chemical is launching its own high-stakes medical cleaning lines to meet new safety standards.

A novel triple-action topical spray for male pattern baldness enters a pivotal clinical trial, potentially disrupting a multi-billion dollar market.

After a period of limited availability, the Ellipsys Vascular Access System is set for a 2026 relaunch, promising a less invasive option for dialysis patients.

The full commercial launch of the Aeros Modular Stem System brings advanced 3D printing and a novel surgical approach to the competitive ankle replacement market.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

Indian pharma giant Lupin acquires European ophthalmology specialist VISUfarma, gaining a major foothold in a market fueled by an aging population.

As cancer strikes younger patients, a new partnership aims to find the disease before symptoms start. But is this new technology ready for prime time?

With FDA approval for a pivotal trial, VDYNE advances its unique valve replacement system, offering new hope for millions with severe tricuspid regurgitation.

A novel transdermal curcumin gel shows significant pain reduction in a clinical trial, offering a potential non-oral alternative for millions with knee pain.